drugset

drugset / Trial / NCT00913419

To Demonstrate the Relative Bioavailability of Cyclobenzaprine HCl Tablets

NCT00913419 ↗

Phase 1 Completed 30 enrolled Sandoz

RandomizedCrossoverOpen-labelTreatment

Summary

To demonstrate the relative bioavailability of Cyclobenzaprine HCl tablets.

Timeline

Start: 1988-11
Primary completion: 1988-12
Completion: 1988-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	cyclobenzaprine	Small molecule	10 mg	—

Indications